22CM
AUPH icon

20/20 Capital Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

20/20 Capital Management’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$171K Buy
+13,173
New +$168K 0.04% 166

Other funds holding AUPH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

20/20 Capital Management's AUPH Position: Q2 2021 in Review

20/20 Capital Management opened a new position in Aurinia Pharmaceuticals (AUPH) in Q2 2021: 13,173 shares worth $171K. The stake represents 0.04% of the portfolio and ranks #166 among its holdings.

167 funds tracked by Wall St. Rank hold AUPH as of Q2 2021.

  • 20/20 Capital Management held 13,173 shares of Aurinia Pharmaceuticals worth $171K as of Q2 2021.
  • Aurinia Pharmaceuticals was a new 20/20 Capital Management position in Q2 2021.
  • Aurinia Pharmaceuticals made up 0.04% of 20/20 Capital Management's portfolio in Q2 2021, its #166 holding.
  • 167 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2021.

Based on 20/20 Capital Management's 13F filing for Q2 2021, filed 12 Jul 2021.